S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
NYSE:VNRX

VolitionRx - VNRX Stock Forecast, Price & News

$2.07
-0.02 (-0.96%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.05
$2.17
50-Day Range
$1.36
$2.38
52-Week Range
$1.31
$3.57
Volume
96,522 shs
Average Volume
136,213 shs
Market Capitalization
$118.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

VolitionRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
141.5% Upside
$5.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.59) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

956th out of 1,027 stocks

Diagnostic Substances Industry

14th out of 14 stocks

VNRX stock logo

About VolitionRx (NYSE:VNRX) Stock

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

VolitionRX Q3 2022 Earnings Preview
VolitionRx Signs Global Supply Deal For Nu.Q Vet Cancer Test
VolitionRx Limited (VNRX)
VolitionRx awarded $1.5M in non-dilutive funding
Volition Achieves CE Mark for Nu.Q® NETs Test
See More Headlines
Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Company Calendar

Last Earnings
11/14/2022
Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Employees
65
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+141.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,820,000.00
Net Margins
-15,452.74%
Pretax Margin
-15,607.46%

Debt

Sales & Book Value

Annual Sales
$90,000.00
Book Value
$0.33 per share

Miscellaneous

Free Float
48,129,000
Market Cap
$118.61 million
Optionable
Optionable
Beta
1.85

Key Executives

  • Dr. Martin Charles Faulkes Ph.D. (Age 78)
    Exec. Chairman
    Comp: $469.37k
  • Mr. Cameron Reynolds MBA (Age 51)
    Founder, Group CEO, Pres & Director
    Comp: $833.54k
  • Mr. Terig Hughes (Age 51)
    Group CFO & Treasurer
    Comp: $288.65k
  • Dr. Jacob Vincent Micallef (Age 66)
    Chief Scientific Officer
    Comp: $571.55k
  • Dr. Salvatore Thomas Butera (Age 71)
    Chief Exec. Officer of Volition Veterinary Diagnostics Devel. LLC
    Comp: $10.3k
  • Dr. Gaetan Michel Ph.D. (Age 49)
    Chief Operating Officer
  • Dr. Mark Eccleston M.B.A. (Age 51)
    Ph.D., Chief Technology Officer
  • Mr. Scott Powell Ph.D. (Age 48)
    Exec. VP of Investor Relations & CFO of Volition America Inc
  • Mr. Nicholas Plummer (Age 51)
    Group Gen. Counsel
  • Ms. Louise Batchelor Day
    Chief Marketing & Communications Officer













VNRX Stock - Frequently Asked Questions

Should I buy or sell VolitionRx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VNRX shares.
View VNRX analyst ratings
or view top-rated stocks.

What is VolitionRx's stock price forecast for 2023?

1 equities research analysts have issued 1 year target prices for VolitionRx's shares. Their VNRX share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 141.5% from the stock's current price.
View analysts price targets for VNRX
or view top-rated stocks among Wall Street analysts.

How have VNRX shares performed in 2022?

VolitionRx's stock was trading at $2.65 at the beginning of the year. Since then, VNRX stock has decreased by 21.9% and is now trading at $2.07.
View the best growth stocks for 2022 here
.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings results on Monday, November, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business earned $0.03 million during the quarter, compared to analyst estimates of $0.05 million. VolitionRx had a negative net margin of 15,452.74% and a negative trailing twelve-month return on equity of 350.45%.

What is VolitionRx's stock symbol?

VolitionRx trades on the New York Stock Exchange (NYSE) under the ticker symbol "VNRX."

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VolitionRx's stock price today?

One share of VNRX stock can currently be purchased for approximately $2.07.

How much money does VolitionRx make?

VolitionRx (NYSE:VNRX) has a market capitalization of $118.61 million and generates $90,000.00 in revenue each year. The company earns $-26,820,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How can I contact VolitionRx?

VolitionRx's mailing address is 13215 BEE CAVE PARKWAY GALLERIA OAKS B SUITE 125, AUSTIN TX, 78738. The official website for the company is www.volitionrx.com. The company can be reached via phone at (646) 650-1351, via email at investorrelations@volition.com, or via fax at 65 32 8172 5651.

This page (NYSE:VNRX) was last updated on 12/8/2022 by MarketBeat.com Staff